search
Back to results

Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy

Primary Purpose

Hilar Cholangiocarcinoma, Primary Sclerosing Cholangitis

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Liver transplantation
45 Gy external radiations
Endoluminal bile duct Brachytherapy
Capecitabine
Pre liver transplantation laparoscopic hand assisted staging
Sponsored by
Azienda Ospedaliera di Padova
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hilar Cholangiocarcinoma focused on measuring Liver transplantation, Neoadjuvant radio- chemo-therapy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Older than 18 years
  • Male or female
  • Diagnosis of Cholangiocarcinoma using:
  • PTBD biopsy or Brushing cytology
  • Ca 19-9>100mg/ml and/or liver mass at CT or MRI with malignant stenosis apperance at Cholangiography,
  • Non resectable tumour araising above the cystic duct
  • Absence of intra and extra hepatic metastasis
  • ECOG score(Eastern Cooperative Oncology Group) 0
  • ASA score (American Society of Anesthesiologists) ≤ 3
  • Ability to understand and willingness to sign the written informed consent form (ICF)

Exclusion Criteria:

  • Intrahepatic Cholangiocarcinoma
  • Non controlled infection
  • Previous radio or chemotherapy
  • Previsous bile duct resection or attempt to resection
  • Intra and/or extrahepatic metastasis
  • Preivious malignant neoplasm (within 5 years)
  • Execution of trans peritoneal biopsy
  • Tumour diameter more than 3 cm

Sites / Locations

  • Azienda Ospedaliera di PadovaRecruiting

Outcomes

Primary Outcome Measures

Percentage of patients free of disease at 24 months post-transplant
Time to recurrence after liver transplant

Secondary Outcome Measures

Progression disease free survival
Overall 2 years survival after liver transplantation
Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis)

Full Information

First Posted
March 7, 2012
Last Updated
July 17, 2012
Sponsor
Azienda Ospedaliera di Padova
search

1. Study Identification

Unique Protocol Identification Number
NCT01549795
Brief Title
Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy
Official Title
Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Unknown status
Study Start Date
January 2012 (undefined)
Primary Completion Date
July 2013 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliera di Padova

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Single-arm pilot clinical trial. Patients with non operable CC associated with PSC will be subjected to liver transplantation after a neoadjuvant multimodal therapy protocol. Cholangiocarcinoma (CC) accounts for 3% of all gastrointestinal cancers; it is more frequent in patients with primary sclerosing cholangitis (PSC), who carry an 8%-12% risk of developing this type of neoplasm. Only a minority of patients are suitable for resection partly because of the anatomic position of the tumor (which often arises from the bile duct bifurcation) and partly because of the frequently coexisting liver disease. In fact, CC is currently considered a major contraindication to liver transplantation (OLT) at the majority of centers, given a 5-year survival rate of 0%-35%. New strategies have been developed for the treatment of this kind of cancer arising in PSC. The Nebraska University group showed a 1 and 3 years survival of 55 and 45 % combining a neoadjuvant intra bile duct barchytherapy and 5-FU based chemotherapy with liver transplantation. University of Pittsburg proposed also a neoadjuvant protocol prior to liver transplantation based on systemic chemotherapy and external radiotherapy reporting a 53% 5 years survival. More convincing results come from the Mayo Clinic. An accurate selection of patients and a proper neoadjuvant multimodal therapy (chemotherapy, external radiotherapy and intraluminal bile duct brachytherapy) lead to a 80% 5 years survival after liver transplantation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hilar Cholangiocarcinoma, Primary Sclerosing Cholangitis
Keywords
Liver transplantation, Neoadjuvant radio- chemo-therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
33 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Liver transplantation
Intervention Description
Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
Intervention Type
Radiation
Intervention Name(s)
45 Gy external radiations
Intervention Description
45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
Intervention Type
Radiation
Intervention Name(s)
Endoluminal bile duct Brachytherapy
Intervention Description
Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
Intervention Type
Drug
Intervention Name(s)
Capecitabine
Intervention Description
Capecitabine - administered till liver transplantation
Intervention Type
Procedure
Intervention Name(s)
Pre liver transplantation laparoscopic hand assisted staging
Intervention Description
Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
Primary Outcome Measure Information:
Title
Percentage of patients free of disease at 24 months post-transplant
Time Frame
24 months
Title
Time to recurrence after liver transplant
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Progression disease free survival
Time Frame
24 months
Title
Overall 2 years survival after liver transplantation
Time Frame
24 months
Title
Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis)
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Older than 18 years Male or female Diagnosis of Cholangiocarcinoma using: PTBD biopsy or Brushing cytology Ca 19-9>100mg/ml and/or liver mass at CT or MRI with malignant stenosis apperance at Cholangiography, Non resectable tumour araising above the cystic duct Absence of intra and extra hepatic metastasis ECOG score(Eastern Cooperative Oncology Group) 0 ASA score (American Society of Anesthesiologists) ≤ 3 Ability to understand and willingness to sign the written informed consent form (ICF) Exclusion Criteria: Intrahepatic Cholangiocarcinoma Non controlled infection Previous radio or chemotherapy Previsous bile duct resection or attempt to resection Intra and/or extrahepatic metastasis Preivious malignant neoplasm (within 5 years) Execution of trans peritoneal biopsy Tumour diameter more than 3 cm
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Umberto Cillo, MD
Phone
+390498218547
Email
cillo@unipd.it
First Name & Middle Initial & Last Name or Official Title & Degree
Enrico Gringeri, MD
Phone
+390498218547
Email
enrico.gringeri@unipd.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Umberto Cillo, MD
Organizational Affiliation
Azienda Ospedaliera di Padova
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Enrico Gringeri, MD
Organizational Affiliation
Azienda Ospedaliera di Padova
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azienda Ospedaliera di Padova
City
Padova
ZIP/Postal Code
35100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Umberto Cillo, MD
Phone
+390498218547
Email
cillo@unipd.it
First Name & Middle Initial & Last Name & Degree
Enrico Gringeri, MD
Phone
+390498218547
Email
enrico.gringeri@unipd.it
First Name & Middle Initial & Last Name & Degree
Umberto Cillo, MD
First Name & Middle Initial & Last Name & Degree
Enrico Gringeri, MD
First Name & Middle Initial & Last Name & Degree
Domenico Bassi, MD
First Name & Middle Initial & Last Name & Degree
Giacomo Zanus, MD
First Name & Middle Initial & Last Name & Degree
Daniele Neri, MD
First Name & Middle Initial & Last Name & Degree
Francesco D'Amico, MD
First Name & Middle Initial & Last Name & Degree
Alessandro Vitale, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
15849505
Citation
Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005 May;241(5):693-9; discussion 699-702. doi: 10.1097/01.sla.0000160701.38945.82.
Results Reference
background
PubMed Identifier
16135931
Citation
Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61. doi: 10.1097/01.sla.0000179678.13285.fa.
Results Reference
background
PubMed Identifier
20497401
Citation
Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010 Jul;23(7):692-7. doi: 10.1111/j.1432-2277.2010.01108.x. Epub 2010 May 20.
Results Reference
background
PubMed Identifier
20556199
Citation
Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics. 2010 Apr 1;2(2):233-243. doi: 10.2217/epi.10.9.
Results Reference
background
Links:
URL
http://www.fegatochirurgia.com
Description
Hepatobiliary surgery and Liver Transplantation Unit, University Hospital of Padua (Italy)

Learn more about this trial

Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy

We'll reach out to this number within 24 hrs